Gianmaria F Bernasconi, Gregorio P Milani, Elisabetta L T De Felice, Craig Laurence, Pietro B Faré, Benedetta Terziroli Beretta-Piccoli, Mario G Bianchetti, Sebastiano A G Lava
{"title":"急性无菌性脑膜炎与三甲双胍和磺胺甲噁唑的时间相关性:系统回顾。","authors":"Gianmaria F Bernasconi, Gregorio P Milani, Elisabetta L T De Felice, Craig Laurence, Pietro B Faré, Benedetta Terziroli Beretta-Piccoli, Mario G Bianchetti, Sebastiano A G Lava","doi":"10.1111/bcp.16346","DOIUrl":null,"url":null,"abstract":"<p><p>Sulphonamides and trimethoprim, although generally well-tolerated, have been temporally associated with aseptic meningitis. To address its presentation and outcome, a literature search was performed. We retained articles reporting patients with features of acute aseptic meningitis following intake of trimethoprim, sulfamethoxazole or sulfisoxazole. A cerebrospinal fluid investigation in ≥1 episode was a prerequisite for inclusion. Sixty articles reporting on 74 patients experiencing a total of 155 episodes were retained. Forty-five (61%) patients had one or more recurrences. Median age at first episode was 43 (interquartile range [IQR] 23-61) years. Symptoms presented within 48 (IQR 6-168) hours of intake at the first episode and within 1.3 (IQR 1-5) hours at recurrences (p < .0001). Cerebrospinal fluid analysis revealed a predominantly neutrophilic (82%, IQR 65%-94%) pleocytosis (180, IQR 38-507 10<sup>6</sup> cells/L), without low glucose or high proteins. Recovery took place within 2 (IQR 1-3) days after stopping the suspected agent. All but one patient completely recovered.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acute aseptic meningitis temporally associated with trimethoprim and sulfamethoxazole: Systematic review.\",\"authors\":\"Gianmaria F Bernasconi, Gregorio P Milani, Elisabetta L T De Felice, Craig Laurence, Pietro B Faré, Benedetta Terziroli Beretta-Piccoli, Mario G Bianchetti, Sebastiano A G Lava\",\"doi\":\"10.1111/bcp.16346\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sulphonamides and trimethoprim, although generally well-tolerated, have been temporally associated with aseptic meningitis. To address its presentation and outcome, a literature search was performed. We retained articles reporting patients with features of acute aseptic meningitis following intake of trimethoprim, sulfamethoxazole or sulfisoxazole. A cerebrospinal fluid investigation in ≥1 episode was a prerequisite for inclusion. Sixty articles reporting on 74 patients experiencing a total of 155 episodes were retained. Forty-five (61%) patients had one or more recurrences. Median age at first episode was 43 (interquartile range [IQR] 23-61) years. Symptoms presented within 48 (IQR 6-168) hours of intake at the first episode and within 1.3 (IQR 1-5) hours at recurrences (p < .0001). Cerebrospinal fluid analysis revealed a predominantly neutrophilic (82%, IQR 65%-94%) pleocytosis (180, IQR 38-507 10<sup>6</sup> cells/L), without low glucose or high proteins. Recovery took place within 2 (IQR 1-3) days after stopping the suspected agent. All but one patient completely recovered.</p>\",\"PeriodicalId\":9251,\"journal\":{\"name\":\"British journal of clinical pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British journal of clinical pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/bcp.16346\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bcp.16346","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Acute aseptic meningitis temporally associated with trimethoprim and sulfamethoxazole: Systematic review.
Sulphonamides and trimethoprim, although generally well-tolerated, have been temporally associated with aseptic meningitis. To address its presentation and outcome, a literature search was performed. We retained articles reporting patients with features of acute aseptic meningitis following intake of trimethoprim, sulfamethoxazole or sulfisoxazole. A cerebrospinal fluid investigation in ≥1 episode was a prerequisite for inclusion. Sixty articles reporting on 74 patients experiencing a total of 155 episodes were retained. Forty-five (61%) patients had one or more recurrences. Median age at first episode was 43 (interquartile range [IQR] 23-61) years. Symptoms presented within 48 (IQR 6-168) hours of intake at the first episode and within 1.3 (IQR 1-5) hours at recurrences (p < .0001). Cerebrospinal fluid analysis revealed a predominantly neutrophilic (82%, IQR 65%-94%) pleocytosis (180, IQR 38-507 106 cells/L), without low glucose or high proteins. Recovery took place within 2 (IQR 1-3) days after stopping the suspected agent. All but one patient completely recovered.
期刊介绍:
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.